medigraphic.com

2001, Number 1-2

<< Back Next >>

Rev Hosp M Gea Glz 2001; 4 (1-2)

Pregnancy from a pharmacological perspective

Villanueva LA

Language: Spanish
References: 32
Page: 32-38
PDF size: 131.04 Kb.


ABSTRACT

The magnitude of drug disposition is influenced for maternal-fetal unit physiological changes. The maternal-fetal unit represents a unique pharmacological state with multiple compartments, wherein the mother-placenta-extramniotic membranes-amniotic fluid and fetus are each represented as a single compartment with different functions and genetics or cellular individual characteristics. It is a problem, which should be focused on several perspectives including epidemiological, pharmacological and toxicological aspects. An understanding of these aspects is essential to rational and effective health public policy on prenatal care.


REFERENCES

  1. Brackbill Y, Mc Manus K, Woodward L. Medicamentos y embarazo. Contacto del niño con los medicamentos y consumo materno. Fondo de Cultura Económica, México, 1988.

  2. Doering PL, Stewart RB. The extent and character of drug consumption during pregnancy. JAMA 1978; 239: 843-848.

  3. Belitzky R. Estudio sobre hábitos y consumo de fármacos en el embarazo. CLAP OPS/OMS 1984; Publicación científica CLAP 1032.

  4. Morris FH, Boyd RDH. Placental transport. In: The physiology of reproduction. Knobil E, Neill J (Eds) Raven Press, Ltd. New York, 1988: 2043-2083.

  5. Gilbert SF. Developmental biology. Sinauer Associates Inc 4a. Ed. Massachussetts, 1994: 633-644.

  6. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38: 203-215.

  7. Mc Bride WG. Thalidomide and congenital anomalies. Lancet 1961; 2: 1358.

  8. Poskanzer D, Herbst AL. Epidemiology of vaginal adenosis and adenocarcinoma associated with exposure to stillbestrol in utero. Cancer 1977; 39: 1892-1895.

  9. Bibbo M, Gill W, Azizi F et al. Follow-up study of male and female offspring of DES- exposed mothers. Obstet Gynecol 1977; 49: 1-8.

  10. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973; 2: 999-1001.

  11. Ernhart CB, Sokol RJ, Martier S et al. Alcohol teratogenicity in the human: a detailed assessment of specificity, critical period and threshold. Am J Obstet Gynecol 1987; 156: 33-39.

  12. Beckman DA, Brent RL. Mechanisms of teratogenesis. Ann Rev Pharmacol Toxicol 1984; 24: 483-500.

  13. Szeto HH, Mann LI, Bhakthavathsalan A, Liu M, Iturrisi CE. Meperidine pharmacokinetics in the maternal-fetal unit. J Pharmacol Exp Ther 1978; 206: 448-459.

  14. Szeto HH. Maternal-fetal pharmacokinetics: Summary and future directions. NIDA Res Monogr 1995; 154: 203-217.

  15. Sohawane BR, Yaffe SS. Physiologic disposition of drugs in the fetus and newborn. In: Drug and chemical action in pregnancy. Fabro S, Scialli AR (Eds) Marcel Dekker. New York, 1986, 103-113.

  16. Juchau MR. The metabolic rate of the placenta. In: Drug and chemical action in pregnancy. Fabro S, Scialli AR (Eds) Marcel Dekker. New York, 1986: 153-163.

  17. Miller RK, Kellogg CK. The pharmacodynamics of prenatal chemical exposure. NIDA Res Monogr 1985: 39.

  18. Ward RM, Mirkin BL. Perinatal/neonatal pharmacology. In: Human pharmacology. Molecular to clinical. Brody TM, Larner J, Minneman KP, Neu HC (Eds.) Mosby-Year Book, Inc St Louis MO, 1993: 843-854.

  19. Cupit GC, Rotmensch HH. Principios de la terapéutica medicamentosa en el embarazo. En: Medicina clínica en obstetricia. Gleicher N (Ed.) Editorial Médica Panamericana. Argentina, 1989: 110-125.

  20. Ward RM. Maternal-placental-fetal unit: Unique problems of pharmacology study. Pediatr Clin North Am 1989; 36: 1075- 1088.

  21. Teasdale F, Jean Jaques G. Morphometric evaluation of the microvillous surface enlargement factor in the human placenta from mild gestation to term. Placenta 1985; 6: 375-381.

  22. Makowski EL, Meschia G, Droegemueller W, Battaglia FC. Measurement of umbilical arterial blood flow to the sheep placenta and fetus in utero. Circ Res 1968; 23: 623-631.

  23. Nau H, Scott WJ. Weak acids may act as teratogens by accumulating in the basic milieu of theearly mammalian embryo. Nature 1986; 323: 276-278.

  24. Farrar HC, Bluner JL. Fetal effects of maternal drug exposure. Ann Rev Pharmacol Toxicol 1991; 31: 525-547.

  25. Green TP, O’Dea RF, Mirkin BL. Determinants of drug disposition and effect in the fetus. Ann Rev Pharmacol Toxicol 1979; 19: 285-322.

  26. Krauer B, Dayer P, Anner R. Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: An analysis of fetal-maternal pairs. Br J Obstet Gynecol 1984; 91: 875-881.

  27. Pelkonen O. Biotransformation of xenobiotics in the fetus. Pharmacol Ther 1980; 10: 261-281.

  28. Dvorchik BH, Woodward G, Sitar DS, Tweed WA. Hidroxylation and glucuronidation of various xenobiotics by hepatic microsomes from the fetal lamb. Dev Pharmacol Ther 1986; 9: 282-289.

  29. Burchell B, Loughtrie M, Jackson M, Harding D, Fournel- Gigleux S et al. Development of human liver UDP-glucuronosyl transferases. Dev Pharmacol Ther 1989; 13: 70-77.

  30. Rudolph AM. Pharmacodynamics in the maternal-fetal-placental unit. NIDA Res Monogr 1995; 154: 152-162.

  31. Briggs GG, Freeman RK, Yaffe SS. Drugs in pregnancy and lactation. Williams and Wilkins. 4a. ed. Baltimore, 1994.

  32. Szeto HH. Pharmacokinetics in the ovine maternal-fetal unit. Ann Rev Pharmacol Toxicol 1982; 22: 221-243.




2020     |     www.medigraphic.com